Delving into the Latest Updates on SeneXta Therapeutics SA with Synapse

Overview

Basic Info

Introduction

SeneXta Therapeutics SA is actively involved in the research and development of therapies targeting neurodegenerative disorders. The company focuses on delivering medicines designed to support healthy brain aging and aid in the rehabilitation process following ischemic brain injury. Founded in 2008 by Enrico Braglia and Federica Pericle, SeneXta Therapeutics is headquartered in Lugano, Switzerland.

This is a randomised, double-blind, group-sequential, placebo-controlled, safety and pharmacokinetic study in healthy, aged volunteers.
Objectives:
to confirm the previously reported safety profile of oral SNX-001 after single and multiple doses of 3.6, 7.2 or 10.8 mg compared to placebo
to establish SNX-001 pharmacokinetic profile.

Start Date01 Dec 2009

Sponsor / Collaborator

SeneXta Therapeutics SA

100 Clinical Results associated with SeneXta Therapeutics SA

Login to view more data

0 Patents (Medical) associated with SeneXta Therapeutics SA

Login to view more data

100 Deals associated with SeneXta Therapeutics SA

Login to view more data

100 Translational Medicine associated with SeneXta Therapeutics SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Methanesulfonyl fluoride ( AChE )	Cognition Disorders More	Discontinued
SNX-002	Neurodegenerative Diseases More	Pending
SNX-003	Neurodegenerative Diseases More	Pending